EE512 Comparing Costs of Immune Checkpoint Inhibitors for Treatment of 1L NSCLC in Colombia – A Cost Minimisation Analysis

Abstract

The Cuenta de Alto Costo estimated 2020 lung cancer prevalence and mortality in Colombia at 8.96 and 2.93 per 100.000, respectively. Non-small-cell lung cancer (NSCLC) accounts for 84% of cases and is associated with short life expectancy. The recent introduction of immune checkpoint inhibitors (ICI) has substantially improved prognosis for patients with advanced NSCLC. In the first-line (1L) setting, these ICIs include nivolumab plus ipilimumab plus chemotherapy (NIVO+IPI+PDC; CheckMate-9LA; regardless of histology or PD-L1) atezolizumab with chemotherapy plus bevacizumab (IMpower150; non-squamous), pembrolizumab monotherapy (KEYNOTE-024; PD-L1>50%), and two regimens combining pembrolizumab and chemotherapy (KEYNOTE-189; non-squamous and KEYNOTE-407; squamous). This study aimed to evaluate total costs of available ICI therapies for treatment of patients with untreated stage IV or recurrent NSCLC in Colombia.